Close Menu

NEW YORK – CareDx reported after the close of the market on Tuesday that its second quarter revenues rose 33 percent year over year, thanks largely to a 41 percent increase in testing services revenues.

For the three months ended June 30, the molecular diagnostics company reported total revenues of $41.8 million, up from $31.5 million during the same period a year earlier, beating the average Wall Street estimate of $35.6 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.